Daniel J. Freeman
14Patents
5h-index
18Co-inventors
63Inventor score
Filing activity: Nov 2, 1995 → Aug 21, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6022737A | Formulations for non-viral in vivo transfection in the lungs | Emerging Cross-Sectional Technologies | 43 | Expired |
| US8771695B2 | Antibodies directed to HER-3 and uses thereof | Chemistry; Metallurgy | 7 | Active |
| US9101760B2 | Material and methods for treating or preventing HER-3 associated diseases | Chemistry; Metallurgy | 6 | Active |
| US7985559B2 | Methods of selecting epidermal growth factor receptor (EGFR) binding agents | Physics | 5 | Active |
| US7981605B2 | Epidermal growth factor receptor mutations | Physics | 5 | Active |
| US9803025B2 | Material and methods for treating or preventing HER-3 associated diseases | Chemistry; Metallurgy | 3 | Active |
| US9988462B2 | Material and methods for treating or preventing HER-3 associated diseases | Chemistry; Metallurgy | 2 | Active |
| US8546107B2 | Epidermal growth factor receptor mutations | Physics | 2 | Active |
| US11873344B2 | Protein biomarker and uses thereof | Physics | 0 | Active |
| US11155876B2 | K-ras mutations and anti-EGFr antibody therapy | Chemistry; Metallurgy | 0 | Active |
| US9097729B2 | Methods of selecting epidermal growth factor receptor (EGFr) binding agents | Physics | 0 | Active |
| US12139549B2 | Material and methods for treating or preventing HER-3 associated diseases | Chemistry; Metallurgy | 0 | Active |
| US11840736B2 | Nucleic acid biomarker and use thereof | Physics | 0 | Active |
| US10030270B2 | K-ras mutations and anti-EGFr antibody therapy | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.